drugset / Trial / NCT03853317
QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy
NaSingle-groupOpen-labelTreatment
Summary
Phase 2, single-arm study to evaluate combination therapy of avelumab, haNK and N-803 in patients with Merkel Cell Carcinoma who have progressed on or after checkpoint inhibitor therapy as assessed by ORR. Patients will receive treatment for a maximum of two years.
Timeline
- Start
- 2020-02-19
- Primary completion
- 2021-09-29
- Completion
- 2022-09-19
Outcome
Outcome not reported
Stopped (Enrollment): “Not meeting recruitment goal”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avelumab | Monoclonal antibody | — | Intravenous |
| Subject | N-803 | Protein / enzyme biologic | — | — |
| Subject | haNK | Cell therapy | — | — |